Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma

Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: Orelabrutinib Sponsor:   Ruijin Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials